
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook due to 5 clinical trials currently in progress, a successful 15-for-1 reverse stock split that has increased its market potential, the appointment of a new CFO with extensive experience in the global life-science industry, and the company's progress in developing Endoxifen for multiple breast-cancer indications. Despite the long development timeline and risks associated with clinical trials, the billion-dollar market potential presents a promising investment opportunity. However, risks to attainment of the company's share price target include balance sheet and liquidity risks, difficulty in obtaining regulatory approvals and suitable reimbursement, competition, and changing macroeconomic factors.
Bears say
Atossa Therapeutics is currently operating at a loss and has no revenue. As a clinical-stage company, their drugs are still in development and face high risks of failure in clinical trials. However, with a potential market worth billions, the potential rewards outweigh the risks in the long term.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares